US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
ES2798263T3
(es)
|
2005-12-08 |
2020-12-10 |
Insmed Inc |
Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
WO2009017802A1
(en)
|
2007-08-01 |
2009-02-05 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Nitro-fattyacid modulation of type ii diabetes
|
ES2535419T3
(es)
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
ES2638448T3
(es)
|
2008-04-15 |
2017-10-20 |
Protiva Biotherapeutics Inc. |
Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
|
ES2692291T3
(es)
|
2008-05-01 |
2018-12-03 |
Complexa Inc. |
Ácidos grasos vinil sustituidos
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
WO2009155439A2
(en)
|
2008-06-19 |
2009-12-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
CN104119242B
(zh)
*
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
AU2015249072C1
(en)
*
|
2008-10-20 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
EP2344639B1
(en)
|
2008-10-20 |
2015-04-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
CN104910025B
(zh)
|
2008-11-07 |
2019-07-16 |
麻省理工学院 |
氨基醇类脂质和其用途
|
SG10201901089TA
(en)
|
2008-11-10 |
2019-03-28 |
Arbutus Biopharma Corp |
Novel lipids and compositions for the delivery of therapeutics
|
WO2010054384A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Lipids and compositions for the delivery of therapeutics
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
CA2751342C
(en)
*
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
NZ594995A
(en)
*
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
AU2010245933B2
(en)
*
|
2009-05-05 |
2016-06-16 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
SMT202100696T1
(it)
|
2009-06-10 |
2022-01-10 |
Arbutus Biopharma Corp |
Formulazione lipidica migliorata
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
JP5894913B2
(ja)
*
|
2009-06-15 |
2016-03-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Pcsk9遺伝子を標的とする、脂質で製剤化されたdsrna
|
EP2449106B1
(en)
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
CA2769624C
(en)
|
2009-07-31 |
2018-09-11 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Electrophilic fatty acid derivatives as anti-inflammatory agents
|
WO2011022460A1
(en)
|
2009-08-20 |
2011-02-24 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
WO2011041639A2
(en)
|
2009-10-02 |
2011-04-07 |
Miller Raymond A |
Heteroatom containing substituted fatty acids
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
HUE038039T2
(hu)
|
2009-12-01 |
2018-09-28 |
Translate Bio Inc |
mRNS bejuttatása fehérjék és enzimek kiegészítésére humán genetikai betegségekben
|
WO2011088309A1
(en)
|
2010-01-14 |
2011-07-21 |
Regulus Therapeutics Inc. |
Microrna compositions and methods
|
WO2011090965A1
(en)
|
2010-01-22 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids for oligonucleotide delivery
|
WO2011127255A1
(en)
|
2010-04-08 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
Preparation of lipid nanoparticles
|
CA2800818C
(en)
|
2010-04-28 |
2017-10-31 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
WO2011136369A1
(ja)
*
|
2010-04-28 |
2011-11-03 |
協和発酵キリン株式会社 |
カチオン性脂質
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
US8865675B2
(en)
|
2010-05-12 |
2014-10-21 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
JP2013527856A
(ja)
*
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
KR20190039347A
(ko)
|
2010-06-03 |
2019-04-10 |
알닐람 파마슈티칼스 인코포레이티드 |
활성제의 전달을 위한 생분해성 지질
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
BR112013000244A2
(pt)
*
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipossomas com lipídeos apresentando pka vantajoso para administração de rna
|
WO2012006376A2
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Virion-like delivery particles for self-replicating rna molecules
|
SI3243526T1
(sl)
|
2010-07-06 |
2020-02-28 |
Glaxosmithkline Biologicals S.A. |
Dostava RNA za sprožitev večih imunskih poti
|
SI2591114T1
(sl)
|
2010-07-06 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Imunizacija velikih sesalcev z majhnimi odmerki RNA
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2012027675A2
(en)
|
2010-08-26 |
2012-03-01 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
US20130253168A1
(en)
|
2010-08-31 |
2013-09-26 |
Steven L. Colletti |
Novel single chemical entities and methods for delivery of oligonucleotides
|
SI2611461T1
(sl)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals Sa |
Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
|
US9549901B2
(en)
|
2010-09-03 |
2017-01-24 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
KR102038241B1
(ko)
|
2010-09-20 |
2019-10-29 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질
|
US9029604B2
(en)
|
2010-09-30 |
2015-05-12 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
BR112013007862A2
(pt)
|
2010-10-01 |
2019-09-24 |
Moderna Therapeutics Inc |
ácidos nucleicos manipulados e métodos de uso dos mesmos.
|
AU2011316707A1
(en)
|
2010-10-11 |
2013-05-09 |
Novartis Ag |
Antigen delivery platforms
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
DK2691443T3
(da)
|
2011-03-28 |
2021-05-03 |
Massachusetts Inst Technology |
Konjugerede lipomerer og anvendelser af disse
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
LT2717893T
(lt)
|
2011-06-08 |
2019-08-12 |
Translate Bio, Inc. |
Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
|
EP4212514A1
(en)
|
2011-06-08 |
2023-07-19 |
Translate Bio, Inc. |
Cleavable lipids
|
ES2656050T3
(es)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinación inmunogénica y usos de las mismas
|
WO2013006825A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Liposomes having useful n:p ratio for delivery of rna molecules
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
US9126966B2
(en)
*
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
KR102014061B1
(ko)
|
2011-10-03 |
2019-08-28 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
|
US9271952B2
(en)
*
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
NZ747501A
(en)
|
2011-10-27 |
2020-05-29 |
Massachusetts Inst Technology |
Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
|
WO2013075035A1
(en)
*
|
2011-11-18 |
2013-05-23 |
Alnylam Pharmaceuticals |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
WO2013086322A1
(en)
*
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
EP3988537A1
(en)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
RS63244B1
(sr)
|
2011-12-16 |
2022-06-30 |
Modernatx Inc |
Kompozicije modifikovane mrna
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
KR20150009952A
(ko)
|
2012-01-27 |
2015-01-27 |
에프. 호프만-라 로슈 아게 |
알파-v-베타-3 발현 세포로의 표적화 전달을 위한 인테그린 안타고니스트 접합체
|
DK2806896T3
(en)
|
2012-01-27 |
2018-03-05 |
Hoffmann La Roche |
Chitosan covalently bound to small molecule integrin antagonist for targeted delivery
|
US9650363B2
(en)
|
2012-01-27 |
2017-05-16 |
Hoffmann-La Roche Inc. |
Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1
|
RU2624731C2
(ru)
|
2012-01-27 |
2017-07-06 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим vla-4
|
CN104321304A
(zh)
|
2012-02-24 |
2015-01-28 |
普洛体维生物治疗公司 |
三烷基阳离子脂质及其使用方法
|
CN102600173B
(zh)
*
|
2012-03-02 |
2013-05-29 |
海南美兰史克制药有限公司 |
氨氯地平/贝那普利药物组合物脂质体固体制剂
|
US10322089B2
(en)
*
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
AU2013237873B2
(en)
*
|
2012-03-29 |
2017-12-14 |
Translate Bio, Inc. |
Ionizable cationic lipids
|
EP2830596B1
(en)
|
2012-03-29 |
2020-12-30 |
Translate Bio, Inc. |
Lipid-derived neutral nanoparticles
|
US9192651B2
(en)
|
2012-04-02 |
2015-11-24 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
JP2015518705A
(ja)
*
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
EP3434667B1
(en)
|
2012-04-19 |
2020-11-04 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
MX2014015041A
(es)
|
2012-06-08 |
2015-06-17 |
Shire Human Genetic Therapies |
Administración pulmonar de arnm a células objetivo no pulmonares.
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
TW201726600A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
WO2014028487A1
(en)
|
2012-08-13 |
2014-02-20 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
EP2925298B1
(en)
|
2012-11-29 |
2019-05-29 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
US20150366997A1
(en)
|
2012-12-07 |
2015-12-24 |
Shire Human Genetics Therapies, Inc. |
COMPOSITIONS AND METHODS FOR mRNA DELIVERY
|
ES2981185T3
(es)
|
2013-03-14 |
2024-10-07 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
CA2903880A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
EP2968586B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Cftr mrna compositions and related methods and uses
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
RS57316B1
(sr)
|
2013-03-15 |
2018-08-31 |
Translate Bio Inc |
Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
CN112618732A
(zh)
|
2013-10-22 |
2021-04-09 |
夏尔人类遗传性治疗公司 |
用于递送信使rna的脂质制剂
|
ES2954366T3
(es)
|
2013-10-22 |
2023-11-21 |
Translate Bio Inc |
Terapia de ácido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa
|
EP3060671B1
(en)
|
2013-10-22 |
2021-12-29 |
Translate Bio, Inc. |
Cns delivery of mrna and uses thereof
|
US9522176B2
(en)
|
2013-10-22 |
2016-12-20 |
Shire Human Genetic Therapies, Inc. |
MRNA therapy for phenylketonuria
|
CA2930973A1
(en)
|
2013-11-22 |
2015-05-28 |
Pal SAERTROM |
C/ebp alpha short activating rna compositions and methods of use
|
CN105939699B
(zh)
|
2013-12-03 |
2020-10-02 |
西北大学 |
脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
|
EP3093283B1
(en)
|
2014-01-09 |
2018-12-19 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
ES2774552T3
(es)
|
2014-03-24 |
2020-07-21 |
Translate Bio Inc |
Terapia de ARNm para el tratamiento de enfermedades oculares
|
SMT202200158T1
(it)
|
2014-04-23 |
2022-05-12 |
Modernatx Inc |
Vaccini ad acidi nucleici
|
BR112016024632A2
(pt)
|
2014-04-25 |
2018-01-30 |
Shire Human Genetic Therapies |
métodos de purificação de rna mensageiro
|
US10238675B2
(en)
|
2014-05-15 |
2019-03-26 |
Insmed Incorporated |
Methods for treating pulmonary non-tuberculous mycobacterial infections
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
EP3587409B8
(en)
|
2014-05-30 |
2022-07-13 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
KR102290205B1
(ko)
|
2014-06-04 |
2021-08-20 |
엑시큐어, 인크. |
예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
|
PE20171238A1
(es)
|
2014-06-24 |
2017-08-24 |
Shire Human Genetic Therapies |
Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
|
IL298516B1
(en)
*
|
2014-06-25 |
2024-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2016002753A1
(ja)
|
2014-06-30 |
2016-01-07 |
協和発酵キリン株式会社 |
カチオン性脂質
|
JP6782171B2
(ja)
|
2014-07-02 |
2020-11-11 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
メッセンジャーrnaのカプセル化
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
CN107106874B
(zh)
|
2014-08-29 |
2021-08-31 |
阿尔尼拉姆医药品有限公司 |
治疗甲状腺素运载蛋白(ttr)介导的淀粉样变性的方法
|
JP6767976B2
(ja)
|
2014-12-05 |
2020-10-14 |
トランスレイト バイオ, インコーポレイテッド |
関節疾患の治療のためのメッセンジャーrna治療法
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
EP3900702A1
(en)
|
2015-03-19 |
2021-10-27 |
Translate Bio, Inc. |
Mrna therapy for pompe disease
|
US11298326B2
(en)
|
2015-03-24 |
2022-04-12 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
EP4026568A1
(en)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
CA2984125A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
AU2016257150B2
(en)
|
2015-05-06 |
2022-03-31 |
Benitec IP Holdings Inc. |
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
|
CN104803863B
(zh)
*
|
2015-05-08 |
2016-07-20 |
厦门成坤生物技术有限公司 |
阳离子类脂化合物及其制备方法
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
EP3310764B1
(en)
|
2015-06-19 |
2023-04-19 |
Massachusetts Institute of Technology |
Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
|
CN107922364B
(zh)
|
2015-06-29 |
2021-12-31 |
爱康泰生治疗公司 |
用于递送核酸的脂质和脂质纳米颗粒制剂
|
EP3303339B1
(en)
|
2015-07-07 |
2021-01-13 |
H. Lundbeck A/S |
Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
|
WO2017008076A1
(en)
*
|
2015-07-09 |
2017-01-12 |
Insmed Incorporated |
Compositions and methods for treating lung diseases and lung injury
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
TW201718638A
(zh)
|
2015-07-21 |
2017-06-01 |
現代治療公司 |
傳染病疫苗
|
SG10201912341SA
(en)
|
2015-07-31 |
2020-02-27 |
Alnylam Pharmaceuticals Inc |
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
CA2995995A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
ES2969082T3
(es)
|
2015-09-17 |
2024-05-16 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
SG10201913953UA
(en)
|
2015-10-02 |
2020-03-30 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
WO2017062513A1
(en)
|
2015-10-05 |
2017-04-13 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
CN108473969B9
(zh)
|
2015-10-14 |
2024-08-23 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
BR112018008051A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacinas de ácido nucleico para vírus de varicella zoster (vzv)
|
SI3718565T1
(sl)
|
2015-10-22 |
2022-08-31 |
Modernatx, Inc. |
Cepiva za respiratorni virus
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
JP6921833B2
(ja)
|
2015-10-22 |
2021-08-18 |
モデルナティーエックス, インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
MA45209A
(fr)
|
2015-10-22 |
2019-04-17 |
Modernatx Inc |
Vaccins contre les maladies sexuellement transmissibles
|
IL286515B2
(en)
|
2015-10-28 |
2024-02-01 |
Acuitas Therapeutics Inc |
Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
|
US12214054B2
(en)
|
2015-11-30 |
2025-02-04 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
CN106883158B
(zh)
*
|
2015-12-15 |
2019-08-23 |
中国科学院广州生物医药与健康研究院 |
生物可降解的氨基脂质类化合物及其制备方法和应用
|
PL3394030T3
(pl)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
|
JP6774965B2
(ja)
|
2015-12-25 |
2020-10-28 |
協和キリン株式会社 |
カチオン性脂質としての化合物
|
CN105622473B
(zh)
*
|
2016-02-06 |
2017-07-25 |
吴国球 |
一种阳离子氨基脂质及其合成方法和用途
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
ES2844180T3
(es)
|
2016-04-08 |
2021-07-21 |
Translate Bio Inc |
Acido nucleico codificante multimérico y usos del mismo
|
CA3020754C
(en)
|
2016-04-14 |
2023-07-25 |
Benitec Biopharma Limited |
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|
EP3452598A4
(en)
|
2016-05-06 |
2020-04-29 |
Exicure, Inc. |
LIPOSOMAL SPHERIC NUCLEIC ACID (SNA) CONSTRUCTS WITH ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC KNOCKDOWN OF INTERLEUKIN-17 RECEPTOR MRNA
|
WO2017201076A1
(en)
*
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
ES2985317T3
(es)
*
|
2016-05-16 |
2024-11-05 |
Univ Texas |
Composiciones para la distribución de ARNt en nanopartículas y procedimientos de uso de las mismas
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
MA45051A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant la relaxine
|
CN109312313A
(zh)
|
2016-06-13 |
2019-02-05 |
川斯勒佰尔公司 |
用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
|
JP6883034B2
(ja)
|
2016-06-24 |
2021-06-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
JP7086870B2
(ja)
*
|
2016-06-30 |
2022-06-20 |
アルブータス・バイオファーマー・コーポレイション |
メッセンジャーrnaを送達するための組成物及び方法
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
AU2017314067A1
(en)
|
2016-08-19 |
2018-12-20 |
CureVac SE |
RNA for cancer therapy
|
CA3038480A1
(en)
|
2016-09-27 |
2018-04-05 |
Kyowa Hakko Kirin Co., Ltd. |
Compound usable as cationic lipid
|
TW201813632A
(zh)
*
|
2016-09-28 |
2018-04-16 |
日商協和醱酵麒麟有限公司 |
含有核酸之脂質奈米粒子
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
US11400109B2
(en)
|
2016-11-10 |
2022-08-02 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger RNA
|
WO2018089801A1
(en)
|
2016-11-10 |
2018-05-17 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
CN110582304A
(zh)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
用于治疗或预防肝脏疾病的rna
|
US11103578B2
(en)
|
2016-12-08 |
2021-08-31 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
ES2949801T3
(es)
|
2017-01-09 |
2023-10-03 |
Whitehead Inst Biomedical Res |
Métodos para alterar la expresión génica mediante la perturbación de multímeros de factores de transcripción que estructuran bucles reguladores
|
EP3568155A4
(en)
|
2017-01-11 |
2020-09-23 |
The Trustees Of The University Of Pennsylvania |
RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
|
MA47515A
(fr)
|
2017-02-16 |
2019-12-25 |
Modernatx Inc |
Compositions immunogènes très puissantes
|
WO2018157154A2
(en)
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Novel codon-optimized cftr mrna
|
US10961184B2
(en)
|
2017-03-07 |
2021-03-30 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
LT3596041T
(lt)
|
2017-03-15 |
2023-01-25 |
Modernatx, Inc. |
Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
EP3596042B1
(en)
|
2017-03-15 |
2022-01-12 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
WO2018167320A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
SG10202110491PA
(en)
|
2017-03-24 |
2021-11-29 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
WO2018200975A1
(en)
|
2017-04-27 |
2018-11-01 |
Vanderbilt University |
Hepatitis c virus gene sequences and methods of use therefor
|
EP4410317A3
(en)
|
2017-04-28 |
2024-10-30 |
Acuitas Therapeutics Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
TWI794237B
(zh)
|
2017-05-31 |
2023-03-01 |
美商奧特吉尼克斯製藥公司 |
Iii 型糖原貯積病治療劑
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
WO2018236849A1
(en)
|
2017-06-19 |
2018-12-27 |
Translate Bio, Inc. |
MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH ATAXIA
|
WO2019008001A1
(en)
|
2017-07-04 |
2019-01-10 |
Curevac Ag |
NEW NUCLEIC ACID MOLECULES
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
EP3662913A4
(en)
|
2017-08-04 |
2021-06-30 |
Kyowa Kirin Co., Ltd. |
Nucleic-acid-containing lipid nanoparticles
|
EP3668833A1
(en)
|
2017-08-16 |
2020-06-24 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
WO2019036000A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
WO2019048645A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
|
CA3075219A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
CA3085442A1
(en)
|
2017-09-19 |
2019-03-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
SG11202002186VA
(en)
|
2017-10-19 |
2020-05-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
WO2019092153A1
(en)
|
2017-11-08 |
2019-05-16 |
Curevac Ag |
Rna sequence adaptation
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
CA3084061A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
IL275567B2
(en)
|
2017-12-27 |
2024-03-01 |
Takeda Pharmaceuticals Co |
Lipid nanoparticle comprising nucleic acid and its use
|
JP7164547B2
(ja)
|
2017-12-27 |
2022-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
WO2019147749A2
(en)
|
2018-01-29 |
2019-08-01 |
Merck Sharp & Dohme Corp. |
Stabilized rsv f proteins and uses thereof
|
US11975110B2
(en)
|
2018-02-02 |
2024-05-07 |
Translate Bio, Inc. |
Cationic polymers
|
EP3752164A1
(en)
*
|
2018-02-12 |
2020-12-23 |
InteRNA Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
WO2019191627A1
(en)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
US12084655B2
(en)
|
2018-04-09 |
2024-09-10 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
EP4242307A3
(en)
|
2018-04-12 |
2023-12-27 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
JP7613685B2
(ja)
|
2018-04-17 |
2025-01-15 |
キュアバック エスイー |
新規rsv rna分子及びワクチン接種用組成物
|
CA3097912A1
(en)
|
2018-05-15 |
2019-11-21 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
WO2019222424A1
(en)
|
2018-05-16 |
2019-11-21 |
Translate Bio, Inc. |
Ribose cationic lipids
|
CN117430538A
(zh)
|
2018-05-24 |
2024-01-23 |
川斯勒佰尔公司 |
硫酯阳离子脂质
|
BR122023022641A2
(pt)
|
2018-05-25 |
2024-02-20 |
Imara Inc. |
Forma cristalina de monoidrato, composição farmacêutica compreendendo a mesma, método de inibição da atividade de pde9 em um paciente e processo para preparar a forma de monoidrato 2
|
JP2021525743A
(ja)
|
2018-05-30 |
2021-09-27 |
トランスレイト バイオ, インコーポレイテッド |
リン酸エステルカチオン性脂質
|
US11547666B2
(en)
|
2018-05-30 |
2023-01-10 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
CN118436618A
(zh)
|
2018-05-30 |
2024-08-06 |
川斯勒佰尔公司 |
信使rna疫苗及其用途
|
CA3101478A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
WO2020023533A1
(en)
|
2018-07-23 |
2020-01-30 |
Translate Bio, Inc. |
Dry power formulations for messenger rna
|
CA3108544A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
KR20210091120A
(ko)
|
2018-08-29 |
2021-07-21 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
|
JP7579239B2
(ja)
|
2018-08-31 |
2024-11-07 |
カーデュリオン・ファーマシューティカルズ・インコーポレイテッド |
鎌状赤血球症を処置するためのpde9阻害剤
|
US20230145188A1
(en)
|
2018-09-14 |
2023-05-11 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
EP3852732A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Peg lipids and uses thereof
|
CA3113651A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
WO2020072324A1
(en)
|
2018-10-01 |
2020-04-09 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
HUE066181T2
(hu)
*
|
2018-10-09 |
2024-07-28 |
Univ British Columbia |
Szerves oldószerektõl és detergensektõl mentes transzfekció-kompetens vezikulumokat tartalmazó készítmények és rendszerek, és az azokkal kapcsolatos eljárások
|
SG11202103745WA
(en)
|
2018-10-18 |
2021-05-28 |
Takeda Pharmaceuticals Co |
Method for activation/proliferation of t cells
|
AU2019362031A1
(en)
|
2018-10-19 |
2021-04-08 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger RNA
|
CN113272282B
(zh)
|
2018-11-09 |
2024-11-08 |
川斯勒佰尔公司 |
具有插入的酯、硫酯、二硫化物和酸酐部分的2,5-二氧代哌嗪脂质
|
BR112021008953A2
(pt)
*
|
2018-11-09 |
2021-08-10 |
Arbutus Biopharma Corporation |
partículas de ácido nucleico-lipídio e de ácido-lipídio, composições, métodos para introduzir um ácido nucleico em uma célula, para distribuição in vivo de um ácido nucleico, para tratar uma doença ou um distúrbio e para preparar um composto, usos de uma partícula, compostos e nanopartícula de lipídio
|
US20220071905A1
(en)
|
2018-11-09 |
2022-03-10 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
AU2019377525A1
(en)
|
2018-11-09 |
2021-05-27 |
Translate Bio, Inc. |
Multi-PEG lipid compounds
|
WO2020097511A2
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
WO2020102172A2
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
US20200157157A1
(en)
|
2018-11-21 |
2020-05-21 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
ES2971849T3
(es)
|
2018-11-21 |
2024-06-10 |
Translate Bio Inc |
Compuestos lipídicos catiónicos y composiciones de los mismos para su uso en la administración de ARN mensajero
|
JP7445657B2
(ja)
|
2018-12-06 |
2024-03-07 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
WO2020146344A1
(en)
|
2019-01-07 |
2020-07-16 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
EP3908568B1
(en)
|
2019-01-11 |
2024-06-26 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
ES2992653T3
(en)
*
|
2019-01-31 |
2024-12-16 |
Modernatx Inc |
Methods of preparing lipid nanoparticles
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
EP3956303A1
(en)
|
2019-04-18 |
2022-02-23 |
Translate Bio, Inc. |
Cystine cationic lipids
|
US20220233444A1
(en)
|
2019-04-22 |
2022-07-28 |
Translate Bio, Inc. |
Thioester cationic lipids
|
WO2020227085A1
(en)
|
2019-05-03 |
2020-11-12 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
US20220218612A1
(en)
|
2019-05-14 |
2022-07-14 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
IL288284B2
(en)
|
2019-05-22 |
2024-06-01 |
Massachusetts Inst Technology |
Circular rna compositions and methods
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
CA3144457A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
ES2992127T3
(es)
|
2019-07-08 |
2024-12-09 |
Translate Bio Inc |
Nanopartículas lipídicas cargadas de ARNm mejoradas y sus procesos de fabricación
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
AU2020315962A1
(en)
|
2019-07-23 |
2022-02-03 |
Translate Bio, Inc. |
Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
|
EP4004220A1
(en)
*
|
2019-07-23 |
2022-06-01 |
Kabushiki Kaisha Toshiba |
Nucleic acid delivery carrier, nucleic acid delivery carrier set, nucleic acid delivery composition, and nucleic acid delivery method
|
CA3148819A1
(en)
|
2019-07-30 |
2021-02-04 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
MX2022001870A
(es)
|
2019-08-14 |
2022-05-30 |
Curevac Ag |
Combinaciones y composiciones de arn con propiedades inmunoestimuladoras disminuidas.
|
EP4031524A1
(en)
|
2019-09-19 |
2022-07-27 |
ModernaTX, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
JP2022548320A
(ja)
|
2019-09-23 |
2022-11-17 |
オメガ セラピューティクス, インコーポレイテッド |
アポリポタンパク質b(apob)遺伝子発現をモジュレートするための組成物および方法
|
EP4041894A1
(en)
|
2019-09-23 |
2022-08-17 |
Omega Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
|
US12076438B2
(en)
|
2019-10-09 |
2024-09-03 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger RNA
|
CN115279418A
(zh)
|
2019-10-21 |
2022-11-01 |
川斯勒佰尔公司 |
信使rna的组合物、方法和用途
|
CA3160739A1
(en)
|
2019-12-04 |
2021-06-10 |
Brian Goodman |
Circular rna compositions and methods
|
EP4076400A1
(en)
|
2019-12-20 |
2022-10-26 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
US20230051811A1
(en)
|
2019-12-20 |
2023-02-16 |
Translate Bio, Inc |
Rectal delivery of messenger rna
|
WO2021123332A1
(en)
|
2019-12-20 |
2021-06-24 |
Curevac Ag |
Lipid nanoparticles for delivery of nucleic acids
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
BR112022014627A2
(pt)
|
2020-02-04 |
2022-09-27 |
Curevac Ag |
Vacina contra coronavírus
|
JOP20220187A1
(ar)
|
2020-02-14 |
2023-01-30 |
Merck Sharp And Dohme Llc |
لقاح فيروس الورم الحليمي البشري (hpv)
|
WO2021173840A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
EP4117725A4
(en)
|
2020-03-09 |
2024-05-29 |
Arcturus Therapeutics, Inc. |
CORONAVIRUS VACCINE COMPOSITIONS AND METHODS
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
MX2022011806A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
WO2021205077A1
(en)
|
2020-04-09 |
2021-10-14 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
EP4143217A4
(en)
|
2020-05-01 |
2024-10-02 |
Arcturus Therapeutics, Inc. |
NUCLEIC ACIDS AND METHODS FOR TREATING CYSTIC FIBROSIS
|
EP4146342A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
US20230190954A1
(en)
|
2020-05-07 |
2023-06-22 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
AU2021269042A1
(en)
|
2020-05-07 |
2023-02-02 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding SARS-CoV-2 antigens
|
EP4149556A1
(en)
|
2020-05-14 |
2023-03-22 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
EP4149425A1
(en)
|
2020-05-15 |
2023-03-22 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
CN116322788A
(zh)
|
2020-05-19 |
2023-06-23 |
奥纳治疗公司 |
环状rna组合物和方法
|
CN116322760A
(zh)
|
2020-05-20 |
2023-06-23 |
旗舰创业创新第六有限责任公司 |
冠状病毒抗原组合物及其用途
|
US20230193311A1
(en)
|
2020-05-20 |
2023-06-22 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
EP3993828A1
(en)
|
2020-05-29 |
2022-05-11 |
CureVac AG |
Nucleic acid based combination vaccines
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
WO2022008613A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
US11976019B2
(en)
|
2020-07-16 |
2024-05-07 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
JP2023535632A
(ja)
|
2020-07-27 |
2023-08-18 |
アンジャリウム バイオサイエンシズ エージー |
Dna分子の組成物、その作製方法、及びその使用方法
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
MX2023001853A
(es)
|
2020-08-14 |
2023-07-07 |
Arcturus Therapeutics Inc |
Método de liofilización de nanopartículas lípidicas.
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
CA3194863A1
(en)
|
2020-10-06 |
2022-04-14 |
Shrirang KARVE |
Improved process and formulation of lipid nanoparticles
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
EP4225272A1
(en)
|
2020-10-12 |
2023-08-16 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
KR20230113580A
(ko)
|
2020-11-25 |
2023-07-31 |
트랜슬레이트 바이오 인코포레이티드 |
안정한 액체 지질 나노입자 제형
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
AU2021409740A1
(en)
|
2020-12-23 |
2023-07-06 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
EP4267740A1
(en)
|
2020-12-28 |
2023-11-01 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
CN116981692A
(zh)
|
2021-01-14 |
2023-10-31 |
翻译生物公司 |
递送mRNA编码的抗体的方法和组合物
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
EP4312999A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
EP4314292A1
(en)
|
2021-03-26 |
2024-02-07 |
MiNA Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
KR20230165276A
(ko)
|
2021-03-31 |
2023-12-05 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
WO2022225918A1
(en)
|
2021-04-19 |
2022-10-27 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
KR20240012370A
(ko)
|
2021-04-20 |
2024-01-29 |
안자리움 바이오사이언시스 아게 |
아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
|
WO2022232289A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
WO2022246568A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Nanovation Therapeutics Inc. |
Kc2-type lipids
|
US20240269302A1
(en)
|
2021-06-11 |
2024-08-15 |
Nibec Co., Ltd. |
Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
EP4362920A1
(en)
|
2021-07-01 |
2024-05-08 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
EP4377331A2
(en)
|
2021-07-30 |
2024-06-05 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (TTR) IRNA compositions and methods of using them
|
CA3229064A1
(en)
|
2021-08-19 |
2023-02-23 |
Andrew Bett |
Thermostable lipid nanoparticle and methods of use thereof
|
CN113461577B
(zh)
*
|
2021-09-01 |
2021-12-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其应用
|
CN115745942A
(zh)
*
|
2021-09-03 |
2023-03-07 |
广州谷森制药有限公司 |
新型阳离子脂质化合物
|
CN117940158A
(zh)
|
2021-09-03 |
2024-04-26 |
库瑞瓦格欧洲公司 |
用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
|
JP2024538489A
(ja)
|
2021-09-03 |
2024-10-23 |
キュアバック エスイー |
核酸を送達するための新規な脂質ナノ粒子
|
CN115745941A
(zh)
*
|
2021-09-03 |
2023-03-07 |
广州谷森制药有限公司 |
新型阳离子脂质化合物
|
CN115772089A
(zh)
*
|
2021-09-07 |
2023-03-10 |
广州谷森制药有限公司 |
新型阳离子脂质化合物
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
EP4419706A1
(en)
|
2021-10-18 |
2024-08-28 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
CN118591398A
(zh)
|
2021-11-10 |
2024-09-03 |
翻译生物公司 |
用于治疗原发性纤毛运动不良症的组合物和方法
|
AU2022397292A1
(en)
|
2021-11-24 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
IL313004A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Coronavirus immunogen compositions and their uses
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
JP2024546855A
(ja)
|
2021-12-17 |
2024-12-26 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
変性条件下での環状rnaの濃縮方法
|
TW202340461A
(zh)
|
2021-12-22 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物和方法
|
KR20240118881A
(ko)
|
2021-12-23 |
2024-08-05 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
WO2023183616A1
(en)
|
2022-03-25 |
2023-09-28 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
CN119136789A
(zh)
*
|
2022-03-28 |
2024-12-13 |
日油株式会社 |
包封核酸的脂质纳米粒子的制造方法和包括该制造方法的药物组合物的制造方法,以及将核酸导入细胞内或靶细胞内的方法
|
WO2023184038A1
(en)
|
2022-04-01 |
2023-10-05 |
Nanovation Therapeutics Inc. |
Mrna delivery method and composition thereof
|
EP4504252A2
(en)
|
2022-04-08 |
2025-02-12 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
WO2023214405A1
(en)
|
2022-05-01 |
2023-11-09 |
Yeda Research And Development Co. Ltd. |
Reexpression of hnf4a to alleviate cancer-associated cachexia
|
AU2023269030A1
(en)
|
2022-05-09 |
2024-11-14 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
WO2023230587A2
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
AU2023299307A1
(en)
|
2022-06-30 |
2025-01-09 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
TW202413424A
(zh)
|
2022-08-01 |
2024-04-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫調節蛋白及相關方法
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
US12221608B2
(en)
|
2022-08-19 |
2025-02-11 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
WO2024049979A2
(en)
|
2022-08-31 |
2024-03-07 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
WO2024086929A1
(en)
*
|
2022-10-25 |
2024-05-02 |
Nanovation Therapeutics Inc. |
Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024112652A1
(en)
|
2022-11-21 |
2024-05-30 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
WO2024119039A2
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticles and uses thereof
|
WO2024119051A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
WO2024121814A1
(en)
|
2022-12-09 |
2024-06-13 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024126809A1
(en)
|
2022-12-15 |
2024-06-20 |
Sanofi |
Mrna encoding influenza virus-like particle
|
WO2024133515A1
(en)
|
2022-12-20 |
2024-06-27 |
Sanofi |
Rhinovirus mrna vaccine
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
WO2024141786A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Multitarget vaccines and therapeutics
|
US20240228949A1
(en)
*
|
2023-01-06 |
2024-07-11 |
Joseph CHALIFOUX |
Method and composition for reprogramming cells
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
疫苗及相關方法
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
WO2024163905A1
(en)
|
2023-02-03 |
2024-08-08 |
Genzyme Corporation |
Hsc-specific antibody conjugated lipid nanoparticles and uses thereof
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫調節組合物及相關方法
|
WO2024165974A1
(en)
*
|
2023-02-09 |
2024-08-15 |
Seqirus Inc. |
Ionizable cationic compound
|
US20240293318A1
(en)
|
2023-02-13 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
US20240285805A1
(en)
|
2023-02-17 |
2024-08-29 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
US20240293582A1
(en)
|
2023-02-17 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
WO2024192420A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024200826A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
WO2024210160A1
(en)
|
2023-04-07 |
2024-10-10 |
Takeda Pharmaceutical Company Limited |
Conjugation complex
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
WO2024216191A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
WO2024218166A1
(en)
|
2023-04-17 |
2024-10-24 |
Sanofi |
Reconstitutable dry powder formulations and methods of use thereof
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024233425A2
(en)
|
2023-05-08 |
2024-11-14 |
Merck Sharp & Dohme Llc |
Polynucleotides encoding norovirus vp1 antigens and uses thereof
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
US20240408188A1
(en)
|
2023-06-09 |
2024-12-12 |
Merck Sharp & Dohme Llc |
Nanoemulsion adjuvant compositions for human papillomavirus vaccines
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
WO2025012756A1
(en)
|
2023-07-07 |
2025-01-16 |
Pfizer Inc. |
Amphiphilic tlr7/8 adjuvants and uses thereof
|
WO2025024486A2
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|